article thumbnail

Clinical Trial: Oral THC Administration Associated with Opioid-Sparing Effects

NORML

Trauma patients administered oral THC consume fewer opioids than do similarly matched controls, according to clinical trial data published in the journal Trauma Surgery & Acute Care.

article thumbnail

Clinical Trial: Cannabinoid Administration Via a Metered-Dose Inhaler Is Safe and Effective for Chronic Pain Patients

NORML

The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Clinical Trial: CBD Administration Reduces Heroin Cravings

NORML

The administration of oral CBD reduces cue-induced cravings and anxiety in subjects with a history of heroin use, according to clinical data published in The American Journal of Psychiatry.

article thumbnail

CDC Seeks Public Comments Regarding Chronic Pain Management

NORML

The call for comments, posted on April 17 at regulations.gov here , states: “Interested persons or organizations are invited to participate by submitting written views, recommendations, and data related to perspectives on and experiences with pain and pain management. percent in 2016).”

article thumbnail

First Ever Clinical Trial for Cannabis Migraine Treatment is Underway

Veriheal

However, there has not been a clinical trial assessing the efficacy of cannabis for migraines, at least not until now. Science Alert has announced that the first clinical trial for cannabis as a migraine treatment is underway. The First Clinical Trial for Migraines and Cannabis.

article thumbnail

Review Paper: Clinical Evidence Lacking in Support of CBD as an Anti-Viral Agent

NORML

There is an absence of clinical data supporting the efficacy of CBD as an antiviral agent, according to a systematic literature review published in the journal Cannabis and Cannabinoid Research. However, this data was based solely on preclinical findings.

CBD 279
article thumbnail

MyMD Pharmaceuticals Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 Vaccine

Cannabis Law Report

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc. Oravax”), partially owned with its majority partner Oramed Pharmaceuticals Inc. About Oravax Medical.